Target intelligence / Profile preview

Respiratory mucosal microbiota

Molecular classification
Other (Microbial community/ecosystem; not an individual molecule, receptor, or protein family)
01

Overview

The **respiratory mucosal microbiota** comprises the diverse community of bacteria, viruses, and fungi that inhabit the mucosal surfaces of the human respiratory tract, including both the upper (nasal passages, sinuses, pharynx) and lower (trachea, bronchi, lungs) airways[1][2]. This microbiota is critical for maintaining respiratory health by providing colonization resistance against pathogens, modulating mucus barrier and immune responses, and contributing to immune training and tolerance[1][2][3]. Dysbiosis (imbalance) of these communities is implicated in respiratory infections, chronic inflammation, asthma, and other lung diseases[2][3]. Unlike classic molecular targets, the respiratory mucosal microbiota defines an ecological system whose composition and function can influence host susceptibility to disease.

Other names
Respiratory tract microbiotaRespiratory mucosal microbial communityRespiratory microbiomeLung microbiotaUpper respiratory tract microbiotaLower respiratory tract microbiota
02

Biological functions

Maintenance of mucosal and immune homeostasisColonization resistance against pathogensModulation of mucus production and barrier functionRegulation of host immune response and immune maturation
03

Disease associations

Infection (role in predisposition/resistance to respiratory infections)Inflammation (implicated in chronic airway inflammation, asthma, COPD)Other (cardiovascular diseases, cancer, general role in host–microbe interactions)
04

Safety considerations

Disruption or depletion can lead to increased susceptibility to respiratory infection (e.g., from antibiotics)Role in chronic inflammation if dysbioticRestorative therapies like probiotics lack precise control and may have unpredictable effects
05

Biomarkers

Microbiota composition signatures (specific shifts in bacterial taxa such as increase/decrease in Proteobacteria, Firmicutes, Bacteroidetes)Microbial diversity indicesPresence or abundance of specific commensals or pathogens (e.g., *Staphylococcus epidermidis*, *Haemophilus influenzae*)

Beyond the preview

Go deeper on Respiratory mucosal microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respiratory mucosal microbiota.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call